Safety of anti-CGRP monoclonal antibodies in patients with migraine during the COVID-19 pandemic : Present and future implications
Copyright © 2021 Sociedad Española de Neurología. Published by Elsevier España, S.L.U. All rights reserved..
BACKGROUND AND OBJECTIVE: CGRP, a neuropeptide involved in migraine pathophysiology, is also known to play a role in the respiratory system and in immunological conditions such as sepsis. We analyzed the impact of the use of CGRP antagonists in patients with migraine during the COVID-19 pandemic, caused by the SARS-CoV-2 coronavirus.
METHODS: This is a multicentre cross-sectional study. From May to November 2020, through a national survey distributed by the Spanish Society of Neurology, we collected data about the presence of COVID-19 symptoms including headache and their characteristics and severity in patients with migraine treated with anti-CGRP monoclonal antibodies (mAb), and compared them with patients with migraine not receiving this treatment. We also conducted a subanalysis of patients with COVID-19 symptoms.
RESULTS: We recruited 300 patients with migraine: 51.7% (155/300) were taking anti-CGRP mAbs; 87.3% were women (262/300). Mean age (standard deviation) was 47.1 years (11.6). Forty-one patients (13.7%) met diagnostic criteria for COVID-19, with no statistically significant difference between patients with and without anti-CGRP mAb treatment (16.1% vs 11.0%, respectively; P=.320). Of the patients with COVID-19, 48.8% (20/41) visited the emergency department and 12.2% (5/41) were hospitalised. Likewise, no clinical differences were found between the groups of patients with and without anti-CGRP mAb treatment.
CONCLUSION: Anti-CGRP mAbs may be safe in clinical practice, presenting no association with increased risk of COVID-19.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:36 |
|---|---|
| Enthalten in: |
Neurologia - 36(2021), 8 vom: 15. Okt., Seite 611-617 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Caronna, E [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Monoclonal |
|---|
| Anmerkungen: |
Date Completed 19.10.2021 Date Revised 23.10.2021 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.nrleng.2021.03.005 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM331949989 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM331949989 | ||
| 003 | DE-627 | ||
| 005 | 20231225214611.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.nrleng.2021.03.005 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1106.xml |
| 035 | |a (DE-627)NLM331949989 | ||
| 035 | |a (NLM)34654536 | ||
| 035 | |a (PII)S2173-5808(21)00160-7 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Caronna, E |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Safety of anti-CGRP monoclonal antibodies in patients with migraine during the COVID-19 pandemic |b Present and future implications |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.10.2021 | ||
| 500 | |a Date Revised 23.10.2021 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 Sociedad Española de Neurología. Published by Elsevier España, S.L.U. All rights reserved. | ||
| 520 | |a BACKGROUND AND OBJECTIVE: CGRP, a neuropeptide involved in migraine pathophysiology, is also known to play a role in the respiratory system and in immunological conditions such as sepsis. We analyzed the impact of the use of CGRP antagonists in patients with migraine during the COVID-19 pandemic, caused by the SARS-CoV-2 coronavirus | ||
| 520 | |a METHODS: This is a multicentre cross-sectional study. From May to November 2020, through a national survey distributed by the Spanish Society of Neurology, we collected data about the presence of COVID-19 symptoms including headache and their characteristics and severity in patients with migraine treated with anti-CGRP monoclonal antibodies (mAb), and compared them with patients with migraine not receiving this treatment. We also conducted a subanalysis of patients with COVID-19 symptoms | ||
| 520 | |a RESULTS: We recruited 300 patients with migraine: 51.7% (155/300) were taking anti-CGRP mAbs; 87.3% were women (262/300). Mean age (standard deviation) was 47.1 years (11.6). Forty-one patients (13.7%) met diagnostic criteria for COVID-19, with no statistically significant difference between patients with and without anti-CGRP mAb treatment (16.1% vs 11.0%, respectively; P=.320). Of the patients with COVID-19, 48.8% (20/41) visited the emergency department and 12.2% (5/41) were hospitalised. Likewise, no clinical differences were found between the groups of patients with and without anti-CGRP mAb treatment | ||
| 520 | |a CONCLUSION: Anti-CGRP mAbs may be safe in clinical practice, presenting no association with increased risk of COVID-19 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Anticuerpos monoclonales | |
| 650 | 4 | |a CGRP | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Migraine | |
| 650 | 4 | |a Migraña | |
| 650 | 4 | |a Monoclonal antibodies | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 7 | |a Antibodies, Monoclonal |2 NLM | |
| 650 | 7 | |a Calcitonin Gene-Related Peptide |2 NLM | |
| 650 | 7 | |a JHB2QIZ69Z |2 NLM | |
| 700 | 1 | |a José Gallardo, V |e verfasserin |4 aut | |
| 700 | 1 | |a Alpuente, A |e verfasserin |4 aut | |
| 700 | 1 | |a Torres-Ferrus, M |e verfasserin |4 aut | |
| 700 | 1 | |a Sánchez-Mateo, N M |e verfasserin |4 aut | |
| 700 | 1 | |a Viguera-Romero, J |e verfasserin |4 aut | |
| 700 | 1 | |a López-Veloso, A C |e verfasserin |4 aut | |
| 700 | 1 | |a López-Bravo, A |e verfasserin |4 aut | |
| 700 | 1 | |a Gago-Veiga, A B |e verfasserin |4 aut | |
| 700 | 1 | |a Irimia Sieira, P |e verfasserin |4 aut | |
| 700 | 1 | |a Porta-Etessam, J |e verfasserin |4 aut | |
| 700 | 1 | |a Santos-Lasaosa, S |e verfasserin |4 aut | |
| 700 | 1 | |a Pozo-Rosich, P |e verfasserin |4 aut | |
| 700 | 0 | |a Spanish CGRP-COVID Study Group |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Neurologia |d 2007 |g 36(2021), 8 vom: 15. Okt., Seite 611-617 |w (DE-627)NLM171204786 |x 2173-5808 |7 nnns |
| 773 | 1 | 8 | |g volume:36 |g year:2021 |g number:8 |g day:15 |g month:10 |g pages:611-617 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.nrleng.2021.03.005 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 36 |j 2021 |e 8 |b 15 |c 10 |h 611-617 | ||